CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 310 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Adult participants aged 18 or older
  • ✓Diagnosed with ulcerative colitis or Crohn's disease per World Gastroenterology Organization guidelines
  • ✓Biologic-naive patients who started biological treatment between June 2011 and June 2013
  • ✓Biological treatment prescribed according to clinical practice (not investigational protocol)
Key exclusion· 2
  • ✕Participating in a clinical trial during the study reference period
  • ✕Unable to understand/complete study questionnaires or provide informed consent per investigator assessment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02861118
NCT02861118N/ACompleted
CompareCT.gov

Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease: VERNE Study

Takeda·observational·Posted Aug 10, 2016·Updated Aug 14, 2019

In Brief

An observational study evaluating No Intervention for Inflammatory Bowel Disease. Completed, enrolled 310 participants across 23 sites.

Detailed Summary

The purpose of this study was to evaluate the impact of the co-morbidities profile on treatment response to biological therapy in inflammatory bowel disease (IBD) participants.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Disease
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 10, 2016
Enrollment StartOct 26, 2016
Primary CompletionApr 4, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago

Interventions

No Interventionother